Page last updated: 2024-11-07

sceptrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

sceptrin: structure given in first source; isolated from marine sponges of the genus Agelas; RN from CHEMLINE [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID157394
CHEMBL ID307456
CHEBI ID80954
MeSH IDM0207439

Synonyms (7)

Synonym
CHEMBL307456
chebi:80954 ,
sceptrin
C17166
79638-16-7
DTXSID00276460
Q15424768
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID379936Antiviral activity against HIV1 in human PBM cells2006Journal of natural products, Dec, Volume: 69, Issue:12
Cyclic heptapeptides from the Jamaican sponge Stylissa caribica.
AID379938Antileishmanial activity against Leishmania donovani2006Journal of natural products, Dec, Volume: 69, Issue:12
Cyclic heptapeptides from the Jamaican sponge Stylissa caribica.
AID477229Cytotoxicity against human KB cells at 30 uM2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Agelastatin E, agelastatin F, and benzosceptrin C from the marine sponge Agelas dendromorpha.
AID468185Displacement of [3H]BQ-123 from human ETA receptor in human SK-N-MC cells at 100 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID379927Antifungal activity against Cryptococcus neoformans2006Journal of natural products, Dec, Volume: 69, Issue:12
Cyclic heptapeptides from the Jamaican sponge Stylissa caribica.
AID468188Displacement of [3H]NPY from neuropeptide Y1 receptor in human SK-N-MC cells at 10 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID468187Displacement of [3H]NPY from neuropeptide Y1 receptor in human SK-N-MC cells at 100 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
AID379937Antimycobacterial activity against Mycobacterium tuberculosis at 128 ug/mL2006Journal of natural products, Dec, Volume: 69, Issue:12
Cyclic heptapeptides from the Jamaican sponge Stylissa caribica.
AID468186Displacement of [3H]BQ-123 from human ETA receptor in human SK-N-MC cells at 10 ug/ml after 60 mins by scintillation counting2009Journal of natural products, Dec, Volume: 72, Issue:12
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (10.00)18.2507
2000's11 (55.00)29.6817
2010's6 (30.00)24.3611
2020's1 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]